Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Alexander T Cohen(St Thomas' Hospital), Victor F. Tapson(Cedars-Sinai Medical Center), Alex C. Spyropoulos(Lenox Hill Hospital), Harry R. Büller(Amsterdam University Medical Centers), Lloyd Haskell(Johnson & Johnson (United States)), Geno J. Merli(Thomas Jefferson University), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Dayi Hu(Beihang University), Sebastian Schellong(Städtisches Klinikum Dresden), Russell D. Hull(Foothills Medical Centre), Theodore E. Spiro(Bayer (United States))
Cited by 603
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
|European Heart Journal|2014|3.1k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k